Nyxoah stock down despite first Genio implant in US Breathe trial
- Posted on September 8, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Nyxoah stock down despite first Genio implant in US Breathe trial
Nyxoah NYXH recently initiated its U.S. post-approval BREATHE study with the first patient implanted using the Genio system, marking an important step in expanding clinical evidence for its obstructive sleep apnea therapy following FDA approval. The milestone reinforces Nyxoah's commercialization strategy by supporting broader physician adoption and future payer engagement in the U.S. market. As the company builds long-term real-world evidence...
